Antiangiogenics
No survival improvement from bevacizumab for patients with newly diagnosed glioblastoma
March 21, 2014Adding bevacizumab (Avastin) to standard chemotherapy and radiation treatment does not improve survival for patients with newly diagnosed glioblastoma, an often deadly brain cancer, researchers reported.
Ramucirumab combination therapy failed to delay progression of advanced breast cancer
December 31, 2013Adding the antibody therapy ramucirumab to docetaxel therapy did not delay disease progression for patients with HER2-negative, advanced breast cancer. These results, from a placebo-controlled, randomized, phase 3 clinical trial, were presented at the 2013 San Antonio Breast Cancer Symposium.
Imaging studies may predict tumor response to antiangiogenic drugs
November 20, 2013Advanced imaging techniques may be able to distinguish which patients' tumors will respond to treatment with antiangiogenic drugs and which will not.
Sign Up for Free e-newsletters
ONA Articles
- Physical Inactivity Linked With Increased Risk of Hodgkin, Non-Hodgkin Lymphoma
- Challenges for Young Adult Couples Facing a Cancer Diagnosis
- Progression-Free Survival Extended With PANEX Protocol in R/R Multiple Myeloma
- Pivot Nurse Improves Patients' Navigation Through Lung Cancer Care
- Following ACS Guidelines Shown to Improve Outcomes for Colon Cancer Survivors
- Letter-Writing Project Communicates Care Wishes to Healthcare Team, Family
- Pivot Nurse Improves Patients' Navigation Through Lung Cancer Care
- Long-term Carfilzomib May Be Safe, Effective In Relapsed Multiple Myeloma
- Palliative Sedation a Valid Option for Refractory Symptoms in End-stage Cancer
- Testicular Cancer Treatment May Increase Risk for Heart Disease in Survivors
- Spotlight on Triptorelin in the Treatment of Premenopausal Women with Early-Stage Breast Cancer
- Redefining Prognosis for Hematologic Cancers in Older Adults by Age
- Outcomes for Elderly With Hematologic Cancers Effected by Cognitive Impairments
- Evolving Role of Radiation Therapy in the Treatment of Mesothelioma
- FDA Approves Fostamatinib for ITP After Insufficient Response to Previous Treatment
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
| Bone Cancer | Regimens | Drugs |
| Brain Cancer | Regimens | Drugs |
| Breast Cancer | Regimens | Drugs |
| Endocrine Cancer | Regimens | Drugs |
| Gastrointestinal Cancer | Regimens | Drugs |
| Genitourinary Cancer | Regimens | Drugs |
| Gynecologic Cancer | Regimens | Drugs |
| Head and Neck Cancer | Regimens | Drugs |
| Hematologic Cancer | Regimens | Drugs |
| Lung Cancer | Regimens | Drugs |
| Other Cancers | Regimens | |
| Rare Cancers | Regimens | |
| Skin Cancer | Regimens | Drugs |